Relay Therapeutics, Inc. (RLAY) · Nov 4, 2026 · Earnings

Relay Therapeutics earnings beat as breast-cancer trial stays on track

Beat — EPS loss of $0.37 vs approximately $0.40 consensus

Relay Therapeutics earnings beat on EPS while ReDiscover-2 enrollment accelerates and ASH becomes the next major zovegalisib catalyst.

Relay is a cash-rich clinical-stage biotech trying to turn zovegalisib into its first commercial product, with its main value now tied to the Phase 3 breast-cancer program and earlier-stage vascular-anomalies data. The quarter adds execution progress, but does not yet provide the clinical efficacy or regulatory evidence needed to materially rewrite that story.

The reported loss beat the published EPS bar. Relay posted a $0.37 quarterly loss per share versus roughly $0.40 expected, a modest improvement against consensus. The beat is useful but not transformative for a company whose economics remain dominated by research spending rather than product revenue.

MetricQ3 2026Q3 2025Consensus / prior period
EPS (Income Statement)-$0.37-$0.43-$0.40 consensus
Revenue (Income Statement)$0$0
R&D expense (Income Statement)$77.1M$68.3M
Cash and investments (Balance Sheet)$848.6M$910.9M at June 30, 2026

The most meaningful operational update is faster Phase 3 enrollment. ReDiscover-2 is now expected to finish enrollment in mid-2027, which management says is approximately one year faster than recent benchmarks. 〔0〕 That improves execution confidence and could bring the pivotal breast-cancer readout closer, but it is still a timing update—not a positive efficacy result.

December is the next real decision point. Relay will present updated ReInspire vascular-anomalies data at ASH and plans to provide a regulatory update afterward. Until those data arrive, the vascular-anomalies opportunity remains promising but unvalidated in this filing.

The balance sheet supports the development plan without an immediate financing overhang. Cash, cash equivalents and investments fell to $848.6 million from $910.9 million at the end of the second quarter, but the company says its resources should fund operations and capital needs into 2029. 〔1〕 That gives Relay room to run the breast-cancer and vascular-anomalies programs while preparing commercially, although R&D expense increased year over year as trial activity expanded.

The new TIE2 program broadens the pipeline but adds no near-term value yet. Relay has announced a mutant-selective TIE2 inhibitor in late-stage preclinical development, alongside hiring a commercial chief and noting the first FDA approval of a molecule discovered on its platform. These are credibility and platform-progress markers, not clinical validation of the lead asset.

Bottom line: This is a modestly constructive quarter: EPS beat, cash remains ample, and the pivotal breast-cancer trial is moving efficiently. The business story still hinges on the December ReInspire data and the eventual Phase 3 zovegalisib readout, so the filing advances execution more than it changes the investment case.

What to watch next

ASH data and regulatory update, December 14, 2026

Original filing on SEC EDGAR

More Relay Therapeutics, Inc. news

Relay Therapeutics earnings beat as breast-cancer trial stays on track | RLAY Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.